Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.

Biotechnology

Triplet Therapeutics

Triplet Therapeutics' headquarters in Cambridge, MA, United States

Nessan Bermingham

Alan J. Buckler

Jia Tay

Eric Sullivan

Jeff Cerio

Irina Antonijevic

Amar Ghodasara

David Morrissey

Amy Lurier

Douglas Kerr

Jean-François Formela

Kathy Biberstein

Nikola Trbovic

Stephen Webster

Shinichiro Fuse

Description

People

Jobs